Navigation Links
Bringing New Cell Therapies to Market Requires Top-Notch Logistics and Operational Efficiency
Date:1/24/2013


According to Mr. O’Donnell, “To develop a commercially viable cell therapy, companies have to consider packaging, storage, inventory management, monitoring systems, distribution, and even clinical site capabilities from the very beginning. Companies that overlook these issues until clinical trials begin can find that they have inadvertently limited their product’s scalability and commercial viability, or incurred unnecessary costs and complications downstream.”
Following his talk, Mr. O’Donnell will also participate in the round table discussion, “What does a commercially successful cell or gene therapy look like?”

The first breakout session following the plenary talks will address commercially feasible manufacturing and business models. Mr. Simpson, Fisher BioServices’ Director of Commercial Operations, will offer his insights on cold chain transport and building efficiency into operational processes, and will discuss recent case studies for allogeneic vs. autologous therapies. He will then participate in a roundtable discussion focused on minimizing the cost of goods and maximizing efficiency of operations.

About Fisher BioServices
Fisher BioServices has 25 years of experience in biological repository/biobanking services, cold chain logistics, and in supporting clinical trials and public health research. The company manages more than 170,000,000 high value biological specimens, cell-based therapeutics, vaccines, tissues, and sample-related data. Fisher BioServices has cGMP compliant repositories, laboratories, and specimen collection kit production and clinical trial support capabilities, depots, and affiliated sites around the world, and serves more than 20 government and hundreds of commercial clients. Fisher BioServices is part of Thermo Fisher Scientific, Inc., the world leader in serving science.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science. The comp
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ORNL wins 9 R&D 100s, bringing total to 173
2. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
3. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
4. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
5. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
6. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
7. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
8. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
9. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
10. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
11. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... DIEGO , April 23, 2015  Neurocrine Biosciences, ... Company will report its first quarter 2015 results before ... Neurocrine will then host a live conference call and webcast ... update Thursday morning, April 30, 2015 at 8:00 a.m. ... can access the live conference call by dialing 866-952-1906 ...
(Date:4/23/2015)... Calif. , April 23, 2015  Veracyte, Inc. (NASDAQ: ... into a definitive agreement to sell approximately $40 million ... the agreement, the investors will purchase an aggregate of ... of $8.15 per share, the closing stock price on ... new and existing investors, including Broadfin Capital, Camber Capital, ...
(Date:4/23/2015)... 23, 2015  Metanome, Inc., an industry leader ... has changed its name to Diversigen, Inc.  The ... the single commercial source for the myriad of ... the diverse opportunities of the microbiome.  From the ... – including those that are difficult to handle, ...
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... Human plasma and serum represents an important biological material for , ... in protein concentration , remains a major ... the very low concentration of biomarker proteins in the presence of high ... strategy is to remove 99% , of ...
... DNeasy Blood & Tissue ... and 96-well-plate,formats. Most samples can be directly lysed with proteinase K, ... for specific sample types provide reproducible purification of high-quality DNA for ... , ...
... Diseases Using the ASCENTATM System , ... Indications , Introduction ... , ESR1 (Estrogen Specific Receptor ... bind to steroid hormones in the cytoplasm, causing their translocation to the ...
Cached Biology Technology:Protein Depletion for Plasma and Serum Proteomic Analysis 2Protein Depletion for Plasma and Serum Proteomic Analysis 3Protein Depletion for Plasma and Serum Proteomic Analysis 4Protein Depletion for Plasma and Serum Proteomic Analysis 5Protein Depletion for Plasma and Serum Proteomic Analysis 6Protein Depletion for Plasma and Serum Proteomic Analysis 7Protein Depletion for Plasma and Serum Proteomic Analysis 8Protein Depletion for Plasma and Serum Proteomic Analysis 9Protein Depletion for Plasma and Serum Proteomic Analysis 10Protein Depletion for Plasma and Serum Proteomic Analysis 11Protein Depletion for Plasma and Serum Proteomic Analysis 12Protein Depletion for Plasma and Serum Proteomic Analysis 13Protein Depletion for Plasma and Serum Proteomic Analysis 14Protein Depletion for Plasma and Serum Proteomic Analysis 15Protein Depletion for Plasma and Serum Proteomic Analysis 16Protein Depletion for Plasma and Serum Proteomic Analysis 17Protein Depletion for Plasma and Serum Proteomic Analysis 18Protein Depletion for Plasma and Serum Proteomic Analysis 19Protein Depletion for Plasma and Serum Proteomic Analysis 20Protein Depletion for Plasma and Serum Proteomic Analysis 21Protein Depletion for Plasma and Serum Proteomic Analysis 22Protein Depletion for Plasma and Serum Proteomic Analysis 23Protein Depletion for Plasma and Serum Proteomic Analysis 24Protein Depletion for Plasma and Serum Proteomic Analysis 25Protein Depletion for Plasma and Serum Proteomic Analysis 26Protein Depletion for Plasma and Serum Proteomic Analysis 27Protein Depletion for Plasma and Serum Proteomic Analysis 28Protein Depletion for Plasma and Serum Proteomic Analysis 29Protein Depletion for Plasma and Serum Proteomic Analysis 30Protein Depletion for Plasma and Serum Proteomic Analysis 31Protein Depletion for Plasma and Serum Proteomic Analysis 32DNA purification from pig ears to bird blood using proven DNeasy Technology 2ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System , Target Validation and Identification of Novel Disease Indications 2ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System , Target Validation and Identification of Novel Disease Indications 3ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System , Target Validation and Identification of Novel Disease Indications 4
(Date:3/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... starting March 30 th . The ... New York markets. Gino ... our new ad campaign following the recent initial shipment of ...
(Date:3/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces its ... of the products featured in 2015 "I Want That" ... PM EST on the DIY Network.   ... Vegas , site of the 2015 International CES ...
(Date:3/18/2015)... Florida , March 18, 2015 ... as businesses, new revolutionary smart wallets and apps continue to ... Companies currently entrenched in the mobile payment industry in focus ... Group Holding Ltd. (NYSE: BABA ), Apple Inc. ... GOOG ) and Facebook Inc. (NASDAQ: FB ) ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... dissolved analytes react with each other? Such information is ... biology, but also in medicine or pharmacy, where it ... method developed in the Institute of Physical Chemistry of ... for determining diffusion coefficients of analytes in fluids and ...
... patients who receive inpatient rehabilitation following discharge from acute-care ... after discharge from the rehabilitation facility according to new ... Journal of the American Medical Association . Before ... frequency and causes of patients returning to hospital after ...
... population will be back in business -- pollinating, making honey and ... species, that means making nests out of plastic waste. A ... of G scientist reveals that some bees use bits of plastic ... was published recently in the journal Ecosphere . It,s ...
Cached Biology News:Capillaries will measure diffusion and help in more efficient medical treatment 2Capillaries will measure diffusion and help in more efficient medical treatment 3UTMB study examines hospital readmission rates after inpatient rehabilitation 2Urban bees using plastic to build hives 2
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
... antibody development to targets including proteins and ... and cancer-specific surface antigens. A&Gs service ... completed in approximately 40 days (duration may ... antigens). Phase I: Immunization, test bleed ...
... ZMD.368. Immunogen: Synthetic peptide derived ... human WNT2B/WNT13 protein. Specificity: Specific ... and rat WNT2B/WNT13 proteins. Recognizes both ... Reactivity: Mouse Human Rat (positive controls: ...
... Immunogen: Synthetic peptide derived from the ... (chromosome 17 open reading frame 37 (C17orf37 ... the C35 protein. On Western blots it ... band. Reactivity: Human (positive control: full-length ...
Biology Products: